FES PET Predicts Response to Endocrine Treatment

June 20, 2012

In patients with newly diagnosed metastatic breast cancer, 18F-fluoroestradiol (FES) positron emission tomography (PET) imaging is a noninvasive measure of breast cancer estrogen-receptor (ER) expression. The results correlate well with standard biopsy and immunohistochemistry measurements and can predict the response of the tumor to endocrine therapy.